Literature DB >> 2332245

Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections.

W R Heizmann1, F Heilmann, B Egeler, H Werner.   

Abstract

Bacterial interactions in mixed infections may interfere with antimicrobial therapy. The in-vitro efficacy of ampicillin alone, combination sulbactam/ampicillin, and metronidazole was studied. Strains of Bacteroides fragilis, Escherichia coli, and Enterococcus faecalis, alone and in association, were tested by means of a broth dilution method. Minimal bactericidal concentrations (MBC) of ampicillin for B. fragilis 74 in association with E. coli 68 were up to 16-fold higher than for B. fragilis 74 alone (256 compared to 16 mg/l), but only 2-fold higher for sulbactam (5 mg/l)/ampicillin (0.5 and 0.25 g/l). Association of B. fragilis 45 and E. faecalis 186 increased ampicillin MBC of E. faecalis 186 from 2 to 16 mg/l, but the combination sulbactam/ampicillin restored activity of ampicillin. In association with E. faecalis, metronidazole MBCs of B. fragilis increased up to 64-fold. Strains of E. faecalis and E. coli were able to destroy 10 mg/l metronidazole within 8 to 20 h. The present experiments demonstrated effectiveness of sulbactam/ampicillin to inhibit beta-lactamases of associated pathogens. Destruction of metronidazole by E. faecalis lends additional support to the use of the combination in aerobic/anaerobic infections including E. faecalis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332245     DOI: 10.1007/bf01641431

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

Review 1.  Recent developments in the understanding of the pathogenesis and treatment of anaerobic infections (2).

Authors:  B Styrt; S L Gorbach
Journal:  N Engl J Med       Date:  1989-07-27       Impact factor: 91.245

Review 2.  Recent developments in the understanding of the pathogenesis and treatment of anaerobic infections (2).

Authors:  B Styrt; S L Gorbach
Journal:  N Engl J Med       Date:  1989-08-03       Impact factor: 91.245

3.  Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci.

Authors:  J E Patterson; M J Zervos
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 4.  Classification of beta-lactamases.

Authors:  A Bauernfeind
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

Review 5.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

Review 6.  Treatment of skin and skin structure infections in the patient at risk.

Authors:  J N Sheagren
Journal:  Am J Med       Date:  1984-05-15       Impact factor: 4.965

7.  Role of Staphylococcus protease in the development of influenza pneumonia.

Authors:  M Tashiro; P Ciborowski; H D Klenk; G Pulverer; R Rott
Journal:  Nature       Date:  1987 Feb 5-11       Impact factor: 49.962

8.  Quantitative aerobic and anaerobic bacteriology of infected diabetic feet.

Authors:  F L Sapico; H N Canawati; J L Witte; J Z Montgomerie; F W Wagner; A N Bessman
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

9.  In vitro activity of ampicillin plus sulbactam against anaerobes compared to ampicillin and cefoxitin.

Authors:  W Heizmann; F Heilmann; H Werner
Journal:  Infection       Date:  1987       Impact factor: 3.553

10.  Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci.

Authors:  I Brook
Journal:  Pediatr Infect Dis       Date:  1985 Sep-Oct
View more
  2 in total

1.  Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery.

Authors:  A Wildfeuer; J Mallwitz; H Gotthardt; E Hille; H Gruber; G Dahmen; G Pfaff; C Göbel
Journal:  Infection       Date:  1997 Jul-Aug       Impact factor: 3.553

2.  Ampicillin and ampicillin-sulbactam dilution tests with mixed cultures of Bacteroides fragilis, Escherichia coli and Enterococcus.

Authors:  F Heilmann
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.